Aneurysmal Subarachnoid Hemorrhage (SAH) - Pipeline Review, Q2 2011

Global Markets Direct, April 2011, Pages: 34

Aneurysmal Subarachnoid Hemorrhage (SAH) - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Aneurysmal Subarachnoid Hemorrhage (SAH) - Pipeline Review, Q2 2011', provides an overview of the Aneurysmal Subarachnoid Hemorrhage (SAH) therapeutic pipeline. This report provides information on the therapeutic development for Aneurysmal Subarachnoid Hemorrhage (SAH), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Aneurysmal Subarachnoid Hemorrhage (SAH). 'Aneurysmal Subarachnoid Hemorrhage (SAH) - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Aneurysmal Subarachnoid Hemorrhage (SAH).
- A review of the Aneurysmal Subarachnoid Hemorrhage (SAH) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Aneurysmal Subarachnoid Hemorrhage (SAH) pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Aneurysmal Subarachnoid Hemorrhage (SAH).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Aneurysmal Subarachnoid Hemorrhage (SAH) pipeline depth and focus of Aneurysmal Subarachnoid Hemorrhage (SAH) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Aneurysmal Subarachnoid Hemorrhage (SAH) Overview
Therapeutics Development
An Overview of Pipeline Products for Aneurysmal Subarachnoid Hemorrhage (SAH)
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics under Development by Companies
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics - Products under Development by Companies
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics Development
Actelion Ltd
Aneurysmal Subarachnoid Hemorrhage (SAH) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Pivlaz - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Simvastatin for Aneurysmal Subarachnoid Haemorrhage (Chinese University of Hong Kong) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tissue Plasminogen Activator - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NimoGel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Magnesium Sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thiola - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics – Drug Profile Updates
Aneurysmal Subarachnoid Hemorrhage (SAH) - Featured News
Sep 27, 2010: Actelion's CONSCIOUS-2 Study With Clazosentan Does Not Meet Primary Endpoint
Nov 12, 2007: Actelion Initiates Phase III Study Of Pivlaz (clazosentan)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Aneurysmal Subarachnoid Hemorrhage (SAH), Q2 2011
Products under Development for Aneurysmal Subarachnoid Hemorrhage (SAH) – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Actelion Ltd, 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Aneurysmal Subarachnoid Hemorrhage (SAH), Q2 2011
Products under Development for Aneurysmal Subarachnoid Hemorrhage (SAH) – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Customers who bought this item also bought

• Aneurysmal Subarachnoid Hemorrhage (SAH) - Pipeline Review, Q4 2010
• Hemorrhage - Pipeline Review, H2 2012
• Hemorrhage - Pipeline Review, H1 2012
• Brain Hemorrhage - Pipeline Review, Q4 2010
• Gastrointestinal Hemorrhage Global Clinical Trials Review, Q2, 2011
• Gastrointestinal Hemorrhage Global Clinical Trials Review, H1, 2013
• Gastrointestinal Hemorrhage Global Clinical Trials Review, H1, 2012
• Transdermal Drug Delivery - Technologies, Markets, and Companies
• Chinese University of Hong Kong - Developmental Therapeutics Review - Q1 2011
• Acute Brain and Spinal Cord Injury. Evolving Paradigms and Management. Neurological Disease and Therapy